TruGenomix Wins Southeast Life Sciences SE Color Pitch

The first SE Color Pitch event, hosted by Southeast Life Sciences, was held on June 24, 2021, featuring top minority-led, early-stage life science companies from the southeast United States.

The winner of the SE Color Pitch event, TruGenomix, which will receive the $10,000 prize, sponsored by Moderna. Presenting for TruGenomix was Charles Cathlin. CEO & Founder.

TruGenomix is a precision behavioral health company focused on advancing the diagnosis and treatment of mental health conditions such as post-traumatic stress disorder (PTSD). Our behavioral health platform incorporates our core products, TruGen-1and TruBase. TruGen-1 is a 1000 gene neuropsychiatric panel, designed in collaboration with Illumina, that includes our patented markers for PTSD predisposition. TruBase is our custom-built machine learning and bioinformatics engine, which is designed to support behavioral health research, clinical decision-making, and biomarker discovery.

See the presentation HERE.

Pascal Medical Corporation Secures $3.8M to Advance ClickGel Into Pivotal Large Animal Testing

Pascal Medical Corporation has raised $3.8 million to push its ClickGel surgical sealant through pivotal large animal testing on the way to human trials. The total combines a $3 million private financing round closed in July with an $800,000 grant from Virginia Catalyst, announced by Governor Abigail Spanberger on July 30, 2026. Pascal will use …

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient …

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation …

News